A detailed history of Jpmorgan Chase & CO transactions in Codexis, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 31,468 shares of CDXS stock, worth $161,116. This represents 0.0% of its overall portfolio holdings.

Number of Shares
31,468
Previous 31,172 0.95%
Holding current value
$161,116
Previous $96,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$2.62 - $3.71 $775 - $1,098
296 Added 0.95%
31,468 $96,000
Q2 2024

Aug 12, 2024

SELL
$2.65 - $3.92 $32,441 - $47,988
-12,242 Reduced 28.2%
31,172 $96,000
Q1 2024

May 10, 2024

SELL
$2.59 - $4.65 $165,208 - $296,609
-63,787 Reduced 59.5%
43,414 $151,000
Q4 2023

Feb 12, 2024

SELL
$1.54 - $3.37 $270,565 - $592,082
-175,692 Reduced 62.11%
107,201 $326,000
Q3 2023

Nov 14, 2023

BUY
$1.5 - $3.75 $106,206 - $265,515
70,804 Added 33.38%
282,893 $534,000
Q2 2023

Aug 11, 2023

BUY
$2.21 - $4.43 $162,061 - $324,856
73,331 Added 52.85%
212,089 $593,000
Q1 2023

May 18, 2023

BUY
$3.81 - $6.76 $178,669 - $317,010
46,895 Added 51.05%
138,758 $574,000
Q1 2023

May 11, 2023

SELL
$3.81 - $6.76 $16,123 - $28,608
-4,232 Reduced 4.4%
91,863 $380,000
Q4 2022

Feb 13, 2023

BUY
$4.26 - $6.84 $158,288 - $254,153
37,157 Added 63.04%
96,095 $448,000
Q3 2022

Nov 14, 2022

SELL
$6.06 - $12.86 $3,211 - $6,815
-530 Reduced 0.89%
58,938 $357,000
Q2 2022

Aug 11, 2022

BUY
$8.35 - $21.89 $61,389 - $160,935
7,352 Added 14.11%
59,468 $622,000
Q1 2022

May 11, 2022

BUY
$16.97 - $31.93 $150,523 - $283,219
8,870 Added 20.51%
52,116 $1.08 Million
Q4 2021

Feb 10, 2022

BUY
$25.61 - $41.78 $412,628 - $673,159
16,112 Added 59.38%
43,246 $1.35 Million
Q3 2021

Nov 12, 2021

BUY
$19.65 - $27.99 $533,183 - $759,480
27,134 New
27,134 $631,000

Others Institutions Holding CDXS

About CODEXIS, INC.


  • Ticker CDXS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,494,100
  • Market Cap $335M
  • Description
  • Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protei...
More about CDXS
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.